Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxytrol For Women Gets OTC Green Light As Rare First-In-Class Switch

This article was originally published in The Tan Sheet

Executive Summary

Despite concerns raised by the Nonprescription Drug Advisory Committee in November, FDA approves Merck’s overactive bladder drug Oxytrol for Women for OTC use. The company plans a launch in the fall.

You may also be interested in...



Top OTC Stories 2013: Switch, Consumer Business Divestment Plans

The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.

Top OTC Stories 2013: Switch, Consumer Business Divestment Plans

The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.

Oxytrol Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant

Merck’s proposed Rx-to-OTC switch of Oxytrol for Women is about identifying symptoms of overactive bladder, not diagnosing the condition, says Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee. Several NDAC members Nov. 9 insisted OAB should be diagnosed before treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel